Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) and Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.
Earnings and Valuation
This table compares Sonoma Pharmaceuticals and Eyepoint Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sonoma Pharmaceuticals | $19.53 million | 0.19 | -$3.17 million | ($0.91) | -0.79 |
| Eyepoint Pharmaceuticals | $31.37 million | 0.64 | -$231.96 million | ($3.96) | -0.06 |
Sonoma Pharmaceuticals has higher earnings, but lower revenue than Eyepoint Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Sonoma Pharmaceuticals and Eyepoint Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sonoma Pharmaceuticals | -7.65% | -4.82% | -1.52% |
| Eyepoint Pharmaceuticals | -13,281.23% | -168.83% | -130.92% |
Risk and Volatility
Sonoma Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500.
Institutional & Insider Ownership
1.9% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent recommendations and price targets for Sonoma Pharmaceuticals and Eyepoint Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sonoma Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Eyepoint Pharmaceuticals | 2 | 9 | 2 | 0 | 2.00 |
Eyepoint Pharmaceuticals has a consensus price target of $21.85, suggesting a potential upside of 9,277.68%. Given Eyepoint Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Sonoma Pharmaceuticals.
Summary
Eyepoint Pharmaceuticals beats Sonoma Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals develops and markets products based on its stabilized hypochlorous acid technology for human and animal health. Its product portfolio includes solutions and gels for wound care, skin conditions, eye care and other hygiene applications. The company’s offerings include Microcyn-branded products, which are used in areas such as wound management and dermatology, as well as products for veterinary care. Sonoma sells its products through commercial partners and distributors in the United States and international markets.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
